Avantor Investor Day Presentation Deck

3. BIOPRODUCTION Recent market evolutions play to Avantor's strengths Biologics (mAbs) Viral Vector / Cell & Gene therapy Bioengineered (mRNA) ~10% of Avantor's Bioproduction revenue¹ Navantor™ - COVID vaccines accelerated platform MARKET TRENDS - Pipeline of mRNA vaccines and therapies 1. FY21 estimates, excluding pending M&A - First RNA drug approval NOVEL CHEMICALS FOR SYNTHETIC BIOLOGY AVANTOR RELEVANCE CUSTOM FORMULATION REAGENTS AND EXCIPIENTS NEW SINGLE-USE FLUID PATHS WITH SPECIALTY MATERIALS 31

View entire presentation